Home | Articles
Published on:May 2020
Indian Journal of Pharmaceutical Education and Research, 2020; 54(2s):s19-s31
Review Article | doi:10.5530/ijper.54.2s.58

Comparability Pathway for the Approval of Similar Biologics with Respect to Reference Biologics in Europe and Brazil

Authors and affiliation (s):

Lakshmi Prasanthi Nori1,*, Prasuna Ravi2

1Department of Pharmaceutics, Chalapathi Institute of Pharmaceutical Sciences, Lam, Guntur, Andhra Pradesh, INDIA.

2Department of Pharmaceutical Management and Regulatory Affairs, CLPT, Lam, Guntur, Andhra Pradesh, INDIA.


The regulatory environment for biologics is continuously evolving, because they are ensuring the targeted therapies for many dreadful diseases. But the high cost of biologics has made the European Union to go for the biosimilar development for the first time after the expiration of patents. The strict requirements by the European Medicines Agency (EMA) guaranteed the highest quality standards. These biosimilars are complex in nature and difficult to characterize because they are extracted from the living sources and requires modern biotechnological methods that differ widely from the conventional drugs. The biosimilarity will be assessed based on the comparability studies where there should not be any traces of clinical differences in terms of quality, safety and efficacy. While the Brazil focused mainly on reducing the cost of biosimilar which are essential in treating many rare and specific diseases which lead to the PPD concept for the sake of the public health care system. Two regulatory pathways are emerged for the biosimilars in Brazil in which the molecules that were licensed through the comparability pathway are only considered as biosimilars. The present article summarizes the development process, regulatory perspectives of biosimilars and related issues that may occur due to interchangeability, extrapolation and International non-proprietary names in EMA, ANVISA and also mentioned about the benefits and purpose of Brazil National Health Surveillance Agency (ANVISA) Partnership for productive development (PPD) concept.

Key words: Biologics, biosimilars, EMA, ANVISA, comparability, International non-proprietary name Partnership for productive development.



Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the 2019 Release of Journal Citation Reports (source: 2018 Web of Science Data).


Impact Factor® as reported in the 2018 Journal Citation Reports® (Clarivate Analytics, 2019): 0.425

User login

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.


IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs